Abstract
Dendritic cells (DC) are the most potent antigen-presenting cells that initiate T cell-mediated immune responses against cancer. It has been almost a decade since the first trial of DC-based cancer immunotherapy was published. Despite the many clinical trials conducted since, few solid conclusions have been reached, and no specificimmunotherapy has routinely demonstrated meaningful anti-tumour responses. Clinical-grade DC can be obtained from three distinct cell populations in the blood - monocytes, CD34+ progenitors or direct isolation of circulating blood DC. This review discusses the science behind DC-based cancer immunotherapy, with a particular emphasis on the use of monocyte-derived DC in melanoma clinical trials, and the various potential avenues for improvement of patient clinical response rates.
Keywords: Dendritic cells, Cancer immunotherapy, Melanoma, Clinical trials
Reviews on Recent Clinical Trials
Title: Dendritic Cell Immunotherapy for Melanoma
Volume: 1 Issue: 2
Author(s): Judy C. Peng, Ranjeny Thomas and Keith Dredge
Affiliation:
Keywords: Dendritic cells, Cancer immunotherapy, Melanoma, Clinical trials
Abstract: Dendritic cells (DC) are the most potent antigen-presenting cells that initiate T cell-mediated immune responses against cancer. It has been almost a decade since the first trial of DC-based cancer immunotherapy was published. Despite the many clinical trials conducted since, few solid conclusions have been reached, and no specificimmunotherapy has routinely demonstrated meaningful anti-tumour responses. Clinical-grade DC can be obtained from three distinct cell populations in the blood - monocytes, CD34+ progenitors or direct isolation of circulating blood DC. This review discusses the science behind DC-based cancer immunotherapy, with a particular emphasis on the use of monocyte-derived DC in melanoma clinical trials, and the various potential avenues for improvement of patient clinical response rates.
Export Options
About this article
Cite this article as:
Peng C. Judy, Thomas Ranjeny and Dredge Keith, Dendritic Cell Immunotherapy for Melanoma, Reviews on Recent Clinical Trials 2006; 1 (2) . https://dx.doi.org/10.2174/157488706776876517
DOI https://dx.doi.org/10.2174/157488706776876517 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Clinical Development of Palbociclib: An Overview
Medicinal Chemistry Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry for Biomarker Discovery in Cutaneous Melanoma
Current Proteomics Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Lycopene Protects Liver Against Ulcerative Colitis
Current Drug Therapy Probiotic Research in Australia, New Zealand and the Asia-Pacific Region
Current Pharmaceutical Design Characterization of Molecular Alterations of BRCA1/2: Analysis and Interpretation Guidelines
Current Women`s Health Reviews The ERp57/GRp58/1,25D3-MARRS Receptor: Multiple Functional Roles in Diverse Cell Systems
Current Medicinal Chemistry Identification of Small Molecule Sulfonic Acids as Ecto-5'-Nucleotidase Inhibitors
Medicinal Chemistry Apoptosis and Apoptosis-Based Therapy in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics A Comprehensive Review on SAR of Curcumin
Mini-Reviews in Medicinal Chemistry Targeting Apoptotic Pathways in Myocardial Infarction: Attenuated by Phytochemicals
Cardiovascular & Hematological Agents in Medicinal Chemistry Hypoxia Responsive Drug Delivery Systems in Tumor Therapy
Current Pharmaceutical Design Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry